09:47:59 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-09-19 Kvartalsrapport 2024-Q2
2024-06-07 Årsstämma 2024
2024-04-18 Bokslutskommuniké 2023
2023-09-28 Kvartalsrapport 2023-Q2
2023-06-12 Ordinarie utdelning EXTX 0.00 NOK
2023-06-09 Årsstämma 2023
2023-04-21 Bokslutskommuniké 2022
2022-09-22 Kvartalsrapport 2022-Q2
2022-06-09 Ordinarie utdelning EXTX 0.00 NOK
2022-06-08 Årsstämma 2022
2022-04-27 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020


ListaEuronext Growth Oslo
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.
2023-09-27 14:55:00
OSLO, 27 September 2023: EXACT THERAPEUTICS AS ("EXACT-Tx", Euronext Growth:
EXTX), a clinical stage precision health company utilising Acoustic Cluster
Therapy (ACT®) across multiple therapeutic areas, is delighted to announce that
Caspar Foghsgaard is joining the company as Senior Vice President Commercial and
Business Development, effective 1 November 2023.

"We are thrilled to welcome Caspar to our leadership team as our Senior Vice
President of Commercial and Business Development. Caspar's extensive experience
and dynamic approach will be instrumental in driving the future growth of
EXACT-Tx. With the recent announcement of the positive initial clinical results
from our ACTIVATE trial, we are entering an exciting phase, during which we will
shape the future of the Company", says Per Walday, CEO of EXACT-Tx.

Caspar Foghsgaard joins Exact Therapeutics from Nykode Therapeutics where his
latest role was as Sr. Director Special Projects and part of the extended
leadership team. He joined Nykode in 2018 and have been closely involved in
Nykode's transformation from a small biotech to a leading company at Oslo Stock
Exchange. Prior to his role as Sr. Director Special Projects, he was heading
Nykode's business development activities as Director Business Development. Other
previous employers include Arcus where he was responsible for business
development in the spirits division and part of the divisional management, and
Elopak as Program Director Strategy. In addition, he has held various business
development and strategy positions including with Novozymes in Denmark, U.S. and

For more information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

About EXACT-Tx:
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to significantly amplify the clinical
utility of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy) and brain diseases.

About ACT®
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.
o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the Company is oncology, however the ACT® platform has
potential across therapeutic areas (CNS, immunotherapy) and product classes.

Forward looking statements: This announcement and any materials distributed in
connection with this announcement may contain certain forward-looking
statements. By their nature, forward-looking statements involve risk and
uncertainty because they reflect the Company's current expectations and
assumptions as to future events and circumstances that may not prove accurate. A
number of material factors could cause actual results and developments to differ
materially from those expressed or implied by this forward-looking statement.